Wells Fargo & Company Contrafect Corp Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.09 - $0.19 $0 - $1	7 Added 2.68%	268 $0
Q3 2022 Nov 14, 2022	SELL	$0.18 - $3.51 $0 - $7	-2 Reduced 0.76%	261 $0
Q2 2022 Aug 12, 2022	BUY	$2.79 - $4.45 $58 - $93	21 Added 8.68%	263 $1,000
Q1 2022 May 16, 2022	BUY	$2.26 - $3.84 $2 - $3	1 Added 0.41%	242 $1,000
Q3 2021 Nov 15, 2021	BUY	$3.19 - $4.43 $66 - $93	21 Added 9.55%	241 $1,000
Q2 2021 Aug 16, 2021	SELL	$3.58 - $4.9 $26,048 - $35,652	-7,276 Reduced 97.07%	220 $1,000
Q1 2021 May 13, 2021	SELL	$4.46 - $6.68 $150,435 - $225,316	-33,730 Reduced 81.82%	7,496 $36,000
Q4 2020 Feb 09, 2021	BUY	$5.05 - $6.4 $50,212 - $63,635	9,943 Added 31.78%	41,226 $209,000
Q3 2020 Nov 05, 2020	BUY	$5.05 - $6.99 $32,027 - $44,330	6,342 Added 25.43%	31,283 $165,000
Q2 2020 Aug 13, 2020	BUY	$4.69 - $7.81 $116,598 - $194,164	24,861 Added 31076.25%	24,941 $159,000
Q1 2020 May 14, 2020	BUY	$5.5 - $12.3 $440 - $984	80 New	80 $0

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.